



#13C  
JB  
(ME)  
7/1/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wei *et al.*

Appl. No. 09/826,212

Filed: April 5, 2001

For: **Tumor Necrosis Factor Receptor 5**

Confirmation No. 3523

Art Unit: 1646

Examiner: O'Hara, E.B.

Atty. Docket:1488.1280006/EKS/GLL/SJE

**Supplemental Amendment and Submission of Substitute Sequence  
Listing Under 37 C.F.R. § 1.825 (a)**

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

MAR 31 2003

TECH CENTER 1600/2900

Sir:

Applicants submit the following Supplemental Amendments and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments (37 C.F.R. § 1.121 and MPEP 714); and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to amend the paper copy of the Sequence Listing.